Published in Cancer on August 15, 2007
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst (2009) 5.62
Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98
Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst (2012) 2.77
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol (2009) 2.61
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer (2009) 2.60
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res (2009) 2.59
Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat (2010) 2.49
Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res (2009) 2.23
BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer (2009) 2.21
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res (2014) 2.18
The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control (2009) 2.14
Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev (2009) 2.00
Breast cancer incidence, stage, treatment and survival in ethnic groups in South East England. Br J Cancer (2009) 1.81
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform (2012) 1.72
Triple-negative breast cancer. Breast Cancer Res (2010) 1.65
African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer (2010) 1.62
Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol (2010) 1.60
Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.59
Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations. Cancer (2011) 1.59
Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2008) 1.53
Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. Breast Cancer Res Treat (2013) 1.53
Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer (2011) 1.48
Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br J Cancer (2009) 1.45
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
Clinical characteristics of breast cancers in African-American women with benign breast disease: a comparison to the surveillance, epidemiology, and end results program. Breast J (2014) 1.39
Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res (2011) 1.37
Breast cancer screening, area deprivation, and later-stage breast cancer in Appalachia: does geography matter? Health Serv Res (2013) 1.32
Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health (2012) 1.26
Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality. Cancer Epidemiol Biomarkers Prev (2008) 1.23
Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev (2008) 1.20
Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions. Cancer Causes Control (2008) 1.19
Ethnic differences in breast cancer survival: status and determinants. Womens Health (Lond Engl) (2011) 1.16
Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res (2008) 1.15
Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control (2011) 1.15
Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev (2014) 1.11
Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer (2011) 1.10
Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res (2012) 1.09
Pilot intervention outcomes of an educational program for biospecimen research participation. J Cancer Educ (2013) 1.08
Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors. Breast Cancer Res (2013) 1.08
Treatment options for patients with triple-negative breast cancer. J Hematol Oncol (2010) 1.07
An assessment of the quality of mammography care at facilities treating medically vulnerable populations. Med Care (2008) 1.04
Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract (2011) 1.03
Triple-negative breast cancers: an updated review on treatment options. Curr Oncol (2011) 1.03
Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PLoS One (2012) 1.00
Triple-Negative Breast Cancer: Clinical and Histological Correlations. Breast Care (Basel) (2011) 1.00
p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6. Nucleic Acids Res (2012) 0.99
Facilitators and barriers to help-seeking for breast and cervical cancer symptoms: a qualitative study with an ethnically diverse sample in London. Psychooncology (2013) 0.96
The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin (2015) 0.94
Temporal trends in the black/white breast cancer case ratio for estrogen receptor status: disparities are historically contingent, not innate. Cancer Causes Control (2010) 0.94
The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis (2014) 0.93
Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat (2013) 0.93
MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. Mol Cancer Res (2014) 0.92
Triple-negative breast cancer. Wien Med Wochenschr (2010) 0.91
Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer. PLoS One (2013) 0.90
Management options in triple-negative breast cancer. Breast Cancer (Auckl) (2011) 0.90
Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer. PLoS One (2012) 0.89
Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. Core Evid (2014) 0.88
Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One (2013) 0.88
Major ethnic group differences in breast cancer screening uptake in Scotland are not extinguished by adjustment for indices of geographical residence, area deprivation, long-term illness and education. Br J Cancer (2012) 0.88
Clinicopathologic features of triple negative breast cancers: an experience from Pakistan. Diagn Pathol (2014) 0.87
Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One (2014) 0.86
Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer (2014) 0.85
Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Des Devel Ther (2009) 0.85
Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) (2014) 0.85
Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients. Mol Clin Oncol (2014) 0.85
Factors associated with willingness to participate in biospecimen research among Chinese Americans. Biopreserv Biobank (2014) 0.85
Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico. Cancer Med (2013) 0.84
Does race affect outcomes in triple negative breast cancer? Breast Cancer (Auckl) (2010) 0.84
CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in situ. Cancer Med (2016) 0.83
The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget (2015) 0.82
Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ? World J Surg (2012) 0.82
There is no association between microRNA gene polymorphisms and risk of triple negative breast cancer in a Chinese Han population. PLoS One (2013) 0.82
Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. Gigascience (2015) 0.81
Culturally appropriate education intervention on biospecimen research participation among Chinese Americans. Cancer Epidemiol Biomarkers Prev (2014) 0.81
Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women. Breast Cancer Res Treat (2011) 0.81
Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget (2016) 0.81
Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer. Oncotarget (2016) 0.80
Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications. Onco Targets Ther (2014) 0.80
Peptide-Based Treatment: A Promising Cancer Therapy. J Immunol Res (2015) 0.80
Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis. Rep Pract Oncol Radiother (2013) 0.80
Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis. Hum Genomics (2010) 0.79
Challenges to developing proteomic-based breast cancer diagnostics. OMICS (2011) 0.79
Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers. Hum Pathol (2015) 0.79
Mammographic and clinicopathological features of triple-negative breast cancer. Br J Radiol (2014) 0.79
Race and the prognostic influence of p53 in women with breast cancer. Ann Surg Oncol (2012) 0.78
Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis. BMC Cancer (2014) 0.78
High levels of BCOX1 expression are associated with poor prognosis in patients with invasive ductal carcinomas of the breast. PLoS One (2014) 0.78
Distinct breast cancer subtypes in women with early-onset disease across races. Am J Cancer Res (2014) 0.78
Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget (2015) 0.78
Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women. ISRN Oncol (2013) 0.78
Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer. Biochem Biophys Res Commun (2016) 0.78
Adaptive immunity programmes in breast cancer. Immunology (2016) 0.77
Comparison of clinicopathologic features and survival in young American women aged 18-39 years in different ethnic groups with breast cancer. Br J Cancer (2013) 0.77
Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. BMC Womens Health (2012) 0.77
The geographic distribution of mammography resources in Mississippi. Online J Public Health Inform (2014) 0.77
Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6. Int J Oncol (2015) 0.77
Enhanced down-regulation of ALCAM/CD166 in African-American Breast Cancer. BMC Cancer (2014) 0.76
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology (2011) 3.52
Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med (2010) 3.21
Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest (2008) 3.11
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol (2004) 2.51
Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol (2003) 2.44
Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther (2009) 2.25
Preoperative and intraoperative predictors of postoperative acute respiratory distress syndrome in a general surgical population. Anesthesiology (2013) 2.22
Point: Efficacy of extracorporeal membrane oxygenation in 2009 influenza A(H1N1): sufficient evidence? Chest (2010) 2.13
Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther (2010) 1.99
Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther (2008) 1.79
Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med (2005) 1.71
Use of sedatives, opioids, and neuromuscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome. Crit Care Med (2008) 1.71
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology (2007) 1.63
Review of a large clinical series: association of cumulative fluid balance on outcome in acute lung injury: a retrospective review of the ARDSnet tidal volume study cohort. J Intensive Care Med (2008) 1.61
Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes (2004) 1.58
The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. Cancer Res (2009) 1.58
A description of intraoperative ventilator management in patients with acute lung injury and the use of lung protective ventilation strategies. Anesthesiology (2011) 1.55
A description of intraoperative ventilator management and ventilation strategies in hypoxic patients. Anesth Analg (2010) 1.52
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer (2004) 1.49
Structure, process, and annual ICU mortality across 69 centers: United States Critical Illness and Injury Trials Group Critical Illness Outcomes Study. Crit Care Med (2014) 1.48
Percutaneous needle vs surgical breast biopsy: previous allegations of overuse of surgery are in error. J Am Coll Radiol (2012) 1.46
Idiopathic granulomatous mastitis masquerading as carcinoma of the breast: a case report and review of the literature. Int Semin Surg Oncol (2007) 1.40
Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res (2005) 1.32
Less is more: improved outcomes in surgical patients with conservative fluid administration and central venous catheter monitoring. J Am Coll Surg (2009) 1.28
Autopsy findings in eight patients with fatal H1N1 influenza. Am J Clin Pathol (2010) 1.25
Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res (2010) 1.23
Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol (2007) 1.22
Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics (2005) 1.21
Independent predictors of acute appendicitis on CT with pathologic correlation. Acad Radiol (2008) 1.18
Scintigraphic imaging of body neuroendocrine tumors. Radiographics (2007) 1.17
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res (2013) 1.16
Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthal Plast Reconstr Surg (2003) 1.15
Concordant loss of fragile gene expression early in breast cancer development. Pathol Int (2005) 1.15
Higher incidence of aggressive breast cancers in African-American women: a review. J Natl Med Assoc (2008) 1.14
Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract (2010) 1.13
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol (2003) 1.12
Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol (2011) 1.12
Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer (2005) 1.11
Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res (2008) 1.09
Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev (2006) 1.08
Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am J Clin Oncol (2003) 1.07
Lung Injury Prevention with Aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ Open (2012) 1.05
Selectively starving cancer cells through dietary manipulation: methods and clinical implications. Future Oncol (2013) 1.05
Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol (2009) 1.03
Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy. Am J Clin Oncol (2005) 1.00
Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat (2011) 1.00
Molecular diagnosis of prostate cancer: are we up to age? Semin Oncol (2013) 0.98
Comparison of lymph node yield in robot-assisted laparoscopic prostatectomy with that in open radical retropubic prostatectomy. BJU Int (2010) 0.98
Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling. Cancer Res (2006) 0.98
Predicting risk of postoperative lung injury in high-risk surgical patients: a multicenter cohort study. Anesthesiology (2014) 0.97
Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis (2009) 0.97
Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Clin Cancer Res (2013) 0.96
Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res (2012) 0.96
Loss of heparan N-sulfotransferase in diabetic liver: role of angiotensin II. Diabetes (2005) 0.94
EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer. Cell Cycle (2013) 0.93
Outcome of Adult Respiratory Failure Patients Receiving Prolonged (≥14 Days) ECMO. Ann Surg (2016) 0.93
Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J (2006) 0.92
Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy (2012) 0.91
Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. Endocrinology (2003) 0.91
Solid serous adenoma of the pancreas: a rare form of serous cystadenoma. Dig Dis Sci (2007) 0.90
Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms. Appl Immunohistochem Mol Morphol (2014) 0.90
Diagnosis, treatment, and management of breast cancer in previously augmented women. Breast J (2006) 0.90
Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, PA. Hum Pathol (2004) 0.89
Sudden-onset thrombocytopenia with oxaliplatin. Ann Intern Med (2003) 0.89
Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther (2010) 0.89
Evaluation of the oxygenation index in adult respiratory failure. J Trauma Acute Care Surg (2014) 0.89
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma. J Gastrointest Surg (2011) 0.89
Imaging spontaneous MMTVneu transgenic murine mammary tumors: targeting metabolic activity versus genetic products. J Nucl Med (2009) 0.87
Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure. Crit Care Med (2010) 0.87
Knockdown of Ki-67 by dicer-substrate small interfering RNA sensitizes bladder cancer cells to curcumin-induced tumor inhibition. PLoS One (2012) 0.87
Prone-positioning therapy in ARDS. Crit Care Clin (2011) 0.86
Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression. J Natl Cancer Inst (2012) 0.84
Primary mucosa-associated lymphoid tissue lymphoma of the breast. Clin Breast Cancer (2008) 0.84
Genomic strategies for diabetic nephropathy. J Am Soc Nephrol (2003) 0.84
STAT5A/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol (2013) 0.84
Characteristics and outcomes of patients hospitalized following pulmonary aspiration. Chest (2014) 0.84
Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation. Breast J (2013) 0.84
Protocols and Hospital Mortality in Critically Ill Patients: The United States Critical Illness and Injury Trials Group Critical Illness Outcomes Study. Crit Care Med (2015) 0.83
Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma. Breast Cancer Res Treat (2010) 0.83
Extracorporeal membrane oxygenation in the context of the 2009 H1N1 influenza A pandemic. Surg Infect (Larchmt) (2011) 0.83
Contemporary ventilator management in patients with and at risk of ALI/ARDS. Respir Care (2013) 0.83
Inferior vena cava filter placement before ECMO decannulation. ASAIO J (2013) 0.82
Compensated hepatitis C: unenhanced MR imaging correlated with pathologic grading and staging. Abdom Imaging (2007) 0.82
American College of Surgeons' Committee on Trauma Performance Improvement and Patient Safety program: maximal impact in a mature trauma center. J Trauma (2011) 0.81
Attitudes and Decisional Conflict Regarding Breast Reconstruction Among Breast Cancer Patients. Cancer Nurs (2016) 0.81
Solitary fibrous tumor of the breast. Breast J (2003) 0.81
Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells. PLoS One (2011) 0.81
Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology (Williston Park) (2007) 0.80
Microarray detection of gene expression changes induced by 1,25(OH)(2)D(3) and a Ca(2+) influx-activating analog in osteoblastic ROS 17/2.8 cells. Steroids (2002) 0.80